Heart
The heart muscle, its valves and its rhythm. (page 3 of 3)
Products 11 written pages
-
Jardiance is the brand name of empagliflozin tablets, an SGLT2 inhibitor. The US FDA approved the application on 1 August 2014. The FDA records fetched here do not say what the medicine was approved...
-
A replacement valve from Medtronic, put in through a catheter, for a failing right ventricular outflow tract (RVOT) conduit (a full conduit of 16 mm or more when implanted, with at least moderate...
-
A device from Abbott for leaky mitral valves. It is delivered through a catheter and is a form of transcatheter edge-to-edge repair. The US FDA approved it in 2013 for people with a degenerative leak...
-
Entresto is the brand name of sacubitril and valsartan tablets, a combination medicine. The US FDA approved the application on 7 July 2015, with priority review. The FDA records fetched here do not...
-
A replacement aortic valve from Edwards Lifesciences that is put in through a catheter, a procedure called TAVR. The US FDA approved it in 2015 for people with severe aortic stenosis who a heart team...
-
A device from Abbott for a leaky tricuspid valve (tricuspid regurgitation). It is delivered through a catheter and is a form of transcatheter edge-to-edge repair. The US FDA approved the TriClip G4...
-
A device used to seal the left atrial appendage (a pouch off the upper left chamber of the heart) so that clots cannot form there and cause a stroke. In the PROTECT AF trial it was placed by...
Technologies 14
-
A cardiac resynchronization device is a type of artificial pacemaker with leads placed at several sites in the heart. The MeSH scope note says such devices treat conduction disturbances that...
-
A drug-eluting stent is a small mesh tube that is placed in an artery to help keep it open and that carries a coating holding a medicine. A US government patient page on angioplasty says that doctors...
-
Using ultrasound to record the size, motion and makeup of the heart and the tissues around it.
-
An ECMO circuit is the equipment set that carries blood out of the body, adds oxygen and returns it. MeSH says the system may consist of a pump, a membrane oxygenator and a heat exchanger. In the...
-
An ICD is a small device that a surgeon places in the chest. It is programmed to detect a dangerous heart rhythm or a cardiac arrest without help, and then gives a strong electric shock to end the...
-
An implantable loop recorder is a heart-rhythm recorder placed under the skin; the manufacturer of one cleared model calls it an insertable cardiac monitor. The device facts on this page come from...
-
The left atrial appendage is a small pouch off the heart's upper left chamber. Closing it off is meant to stop clots from forming there and causing a stroke. A US government patient page describes...
-
A left ventricular assist device (LVAD) is a pump that helps the left ventricle move blood. MeSH describes heart-assist pumps as small, often implantable, with a pumping chamber and a power source...
-
A pacemaker is a device that uses electric impulses to make the heart muscle contract. MeSH says it may be temporary (external) or permanent (internal or internal-external). A MedlinePlus page says a...
-
Watches and similar worn devices can check the pulse with light sensors and flag a pulse pattern that may be atrial fibrillation. A flag is a prompt to get checked, not a diagnosis. In the Apple...
-
A replacement heart valve is a device that takes the place of a diseased heart valve. A US government vocabulary entry says it may be made of biological material, synthetic material or both. A US...
-
Temporary mechanical circulatory support means a pump or similar device that helps the heart pump blood for a limited time. A 2026 review of randomized trials in adults with cardiogenic shock after a...
-
A way to repair a leaking heart valve with a device delivered by a catheter, a thin tube passed through a blood vessel. The name is short for transcatheter edge-to-edge repair. It is used on the...
-
No source read defines a wearable ECG patch as a class. The nearest MeSH heading is Wearable Electronic Devices, which MeSH describes as electronic implements worn on the body. This page therefore...
Biomarkers 3
-
Blood tests that measure proteins the heart makes in larger amounts when it has to work harder. MedlinePlus says they are mainly used to help confirm or rule out heart failure in people who have...
-
A percentage that estimates the chance of a cardiovascular disease event over the next ten years in a person who does not already have cardiovascular disease. Prevention guidance uses it, together...
-
A percentage that says how much of the blood in the left ventricle, the heart's lower left chamber, the heart pushes out on each beat. It shows how well the heart pumps. Doctors use it to sort heart...
Care pathways 1
-
The steps that an ACC summary of the 2023 guideline gives for lowering stroke risk in atrial fibrillation: estimate the risk with a validated score, base stroke-reducing treatment on that risk, favor...
Risk factors 2
-
Not getting regular physical activity. WHO lists it as a modifiable risk factor for high blood pressure. In the United States, 29.1% of adults were physically inactive in 2015 to 2016, down from...
-
The smoking of tobacco, as opposed to smoking other substances.
Guidelines 17
-
A 2017 guideline on ventricular arrhythmias and on stopping sudden cardiac death, issued jointly by the Heart Rhythm Society, American College of Cardiology and the American Heart Association. PubMed...
-
The 2019 guideline from the American College of Cardiology and the American Heart Association on the primary prevention of cardiovascular disease. PubMed holds no abstract for it, so this page gives...
-
The 2020 guideline on the management of people with heart valve disease from the American College of Cardiology and the American Heart Association. An ACC summary says it replaces the 2014 guideline...
-
The 2022 heart failure guideline from the American Heart Association, the American College of Cardiology and the Heart Failure Society of America. Its abstract says it replaces the 2013 guideline and...
-
The 2023 guideline on diagnosing and managing atrial fibrillation from the American College of Cardiology and the American Heart Association, with two more societies abbreviated in its title (ACCP...
-
The 2024 US guideline on the management of hypertrophic cardiomyopathy, issued by the American Heart Association and the American College of Cardiology with four other societies named in its title...
-
The 2024 atrial fibrillation guidelines of the European Society of Cardiology, developed jointly with a European cardio-thoracic surgery association. The ESC page says they are built around a...
-
The 2025 valvular heart disease guidelines of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery. Only the title, the publication details and the ESC page...
-
The 2026 guideline from the American College of Cardiology and the American Heart Association, with other societies named in its title, on managing dyslipidemia: high blood cholesterol, high...
-
The 2026 heart failure guidelines of the European Society of Cardiology. The ESC page says they refine how heart failure is classified by ejection fraction, add a stage-based classification with more...
-
The 2023 guideline of the European Society of Cardiology on acute coronary syndromes. The ESC page says it covers the whole range of these syndromes in one document, where earlier ESC guidelines...
-
A named, linked entry for the UK NICE guideline NG106 on chronic heart failure in adults. It gives no recommendations.
-
A named, linked entry for the UK NICE guideline NG196 on diagnosing and managing atrial fibrillation. It gives no recommendations.
-
A named, linked entry for the UK NICE guideline NG238 on assessing and reducing the risk of cardiovascular disease, including lipid modification. It gives no recommendations.
-
The 2022 recommendation statement issued by the US Preventive Services Task Force on taking low-dose aspirin to prevent cardiovascular disease in adults who do not already have it. Its advice differs...
-
The 2022 statement issued by the US Preventive Services Task Force on screening adults aged 50 or older, who have no symptoms, for atrial fibrillation. The Task Force found the evidence insufficient...
-
The 2022 recommendation statement issued by the US Preventive Services Task Force on taking a statin to prevent cardiovascular disease in adults who do not already have it. The Task Force grades its...
Studies 22 written pages
-
A large trial that compared the blood thinner apixaban with warfarin in people with atrial fibrillation who had at least one other risk factor for stroke. The authors conclude that apixaban prevented...
-
A trial in US adults with NYHA class III heart failure and a past hospital stay for heart failure. The registry results describe 550 implanted patients, and the registry says the sensor is implanted...
-
A trial in 614 people with heart failure and a leaking mitral valve caused by the weak heart muscle, who still had symptoms on maximal medicines. Adding the MitraClip device to medicines led to fewer...
-
A large trial in adults with heart failure whose ejection fraction was reduced (40% or less) who were already taking recommended treatment. About half were given dapagliflozin 10 mg once a day and...
-
A large trial of people with type 2 diabetes who had heart or blood-vessel disease or were at risk of it. They took dapagliflozin 10 mg a day or placebo. Dapagliflozin did not lower the rate of the...
-
A large trial in adults with heart failure and an ejection fraction above 40%, which covers mildly reduced and preserved values. About half were given dapagliflozin 10 mg once a day and half a...
-
A trial in 901 people aged 65 or older with severe aortic stenosis but no symptoms. It compared early TAVR (with the SAPIEN 3 valve) against clinical surveillance. Fewer people in the TAVR group had...
-
A large trial of people with type 2 diabetes at high risk of heart and blood-vessel disease. They took empagliflozin 10 mg or 25 mg a day, or placebo, on top of usual care. Empagliflozin lowered the...
-
A large trial in adults with heart failure and an ejection fraction above 40%. About half were given empagliflozin 10 mg once a day and half a placebo, on top of usual treatment. Over a median of...
-
A large trial in adults with heart failure whose ejection fraction was reduced (40% or less) who were already taking recommended treatment. About half were given empagliflozin 10 mg once a day and...
-
A trial that compared TAVR (with a self-expanding Medtronic valve) against open-heart surgery in 1468 people who had severe aortic stenosis and a low risk from surgery. After two years, the rate of...
-
A large trial of exercise training in adults who had chronic heart failure with a reduced ejection fraction (the heart pumps out a smaller share of its blood). About half were assigned usual care...
-
A large trial in adults with heart failure whose ejection fraction was reduced (40% or less). It compared LCZ696, a combination of sacubitril and valsartan, with enalapril, each added to recommended...
-
A trial that compared TAVR (with the SAPIEN 3 valve) against open-heart surgery in 1000 people who had severe aortic stenosis and a low risk from surgery. After one year, fewer people in the TAVR...
-
A Spanish trial of a Mediterranean-style diet to lower the chance of heart attacks and strokes in people at high cardiovascular risk who did not yet have cardiovascular disease. 7447 people aged 55...
-
A trial that compared closing off the left atrial appendage with the WATCHMAN device against warfarin, in adults with non-valvular atrial fibrillation who were eligible for warfarin. For stroke...
-
A large trial that compared two doses of the blood thinner dabigatran with warfarin in people with atrial fibrillation at risk of stroke. The higher dose (150 mg twice daily) gave fewer strokes or...
-
A large trial that compared the blood thinner rivaroxaban with warfarin in people with non-valvular atrial fibrillation at increased risk of stroke. Rivaroxaban was shown to be no worse than warfarin...
-
A European trial in adults aged 65 or older who had had a heart attack in the previous 6 months and had at least one further risk condition. 2499 patients were randomized to a once-daily polypill...
-
A large trial of adults aged 45 and over who already had heart or blood-vessel disease and were overweight or obese but did not have diabetes. Half took semaglutide 2.4 mg once a week and half took...
-
A large trial of people with type 2 diabetes and heart or blood-vessel disease that compared tirzepatide with dulaglutide, another weekly diabetes injection that has been shown to lower the chance of...
-
A trial in 350 people with severe tricuspid regurgitation (a leaking valve between the right upper and lower chambers) and symptoms. It compared the TriClip device plus medicines against medicines...
Organizations 4 written pages
-
A company based in the United States (ROR types: company and funder). US regulatory records name ABBOTT MEDICAL as the applicant for the approvals of MitraClip, TriClip and the Amplatzer Septal...
-
An association for cardiovascular and pulmonary rehabilitation. Its full name is in the title of a 2019 scientific statement on home-based cardiac rehabilitation, written with two other US societies.
-
A company based in the United States (ROR types: company and funder). US regulatory records name Edwards Lifesciences, LLC as the applicant for the approval of the SAPIEN 3 heart valve...
-
A company based in the United States (ROR types: company and funder). US regulatory records name Medtronic, Inc. as the applicant for the approvals of the CoreValve and Evolut heart valves and the...
Resources 2
-
A US national initiative whose target year is 2027 and whose aim is to prevent one million heart attacks and strokes. Its website says the CDC and CMS co-lead it and that it began in 2012. Its...
-
A toolkit from Million Hearts, developed with the rehabilitation association AACVPR, for hospital and cardiac rehabilitation teams that want more eligible patients to take part. It lists changes a...
Guides 4
-
What atrial fibrillation (AF) is, how the sources link it to stroke, what blood thinners and a left atrial appendage closure device are, how the sources describe bleeding, and questions to ask a care...
-
What DVT (deep vein thrombosis) and PE (pulmonary embolism) are, how MedlinePlus describes their symptoms, risk factors and treatment, what blood thinners are, and questions to ask a care team.
-
What cardiomyopathy is, the hypertrophic and dilated kinds as MedlinePlus Genetics describes them, how MedlinePlus describes amyloidosis, and questions to ask a care team.
-
What heart valve disease is, how MedlinePlus and NHLBI describe treating it, what four trials of a catheter valve (TAVR) found, and questions to ask a care team.
Reading paths 2
-
A suggested order for reading this atlas for an adult who has had a heart event or procedure, or has been told to look after their heart, and for their family. It starts with everyday heart-healthy...
-
A suggested order for reading this atlas, for an adult who has just been told they have heart failure, and for their family. It starts with what heart failure is and how doctors sort it into types...
Bottlenecks 3
-
Only about 1 in 4 people who were eligible for cardiac rehabilitation under Medicare in 2016 attended any sessions. In a study of Medicare fee-for-service beneficiaries, 24.4% took part, fewer took...
-
In a US registry of outpatients with heart failure with reduced ejection fraction, many people who could take each recommended medicine class were not prescribed it, and few of those who were...
-
In many places where rheumatic heart disease is common, WHO says treatment of strep throat at an early stage is often not achieved, and many people are diagnosed late. In many of these countries...
Ideas 2
-
The idea is to offer cardiac rehabilitation at home, with remote coaching and indirect supervision of exercise, instead of only in a supervised center. A joint scientific statement from...
-
The idea is to aim to raise heart-failure medicines to full recommended doses within about 2 weeks of leaving hospital, with several close follow-up visits, instead of leaving it to usual practice...
Registry records 3,818
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials. Registry trials are filed under a term by the conditions they are linked to, so a term can hold trials of a related condition. Its count can be higher than the count on the condition's own page.
Registry products 196
-
A biologics license application (BLA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A premarket notification (510(k)) in FDA's device records. FDA's decision is recorded as substantially equivalent (code SESE).
-
A premarket notification (510(k)) in FDA's device records. FDA's decision is recorded as substantially equivalent (code SESE).
-
A premarket notification (510(k)) in FDA's device records. FDA's decision is recorded as substantially equivalent (code SESE).
-
A premarket notification (510(k)) in FDA's device records. FDA's decision is recorded as substantially equivalent (code SESE).
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record. FDA lists it under 4 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record. FDA lists it under 3 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.